Trial Profile

A Phase 1/2, First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-023 as a Single Agent, and in Combination With AVZO-021 and/or Endocrine Therapy in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 09 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ARTS 021 (Primary) ; AVZO 023 (Primary) ; Fulvestrant (Primary) ; Letrozole (Primary)
Indications HER2 negative breast cancer; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Avenzo Therapeutics

09 Jun 2025 New trial record
05 Jun 2025 According to a Avenzo Therapeutics media release, company announced initiation of this Phase 1/2 clinical study.
05 Jun 2025 Status changed from not yet recruiting to recruiting according to a Avenzo Therapeutics media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com